Data is available for up to 223 463 individuals from 43 genetic studies has just been released by a Lancet Publication. it is now clear that the cholesterol control drugs-Statins increase the risk of new-onset type 2 diabetes mellitus. We aimed to assess whether this increase in risk is a consequence of inhibition of 3-hydroxy-3-methylglutaryl-CoA reductase (HMGCR), the intended drug target.
Some other side effects reported for statins are:
- SIDE EFFECTS
- Hepatic dysfunction
- Muscle injury
- Renal dysfunction
- Behavioral and cognitive
- Diabetes mellitus
- Risks in pregnancy and breastfeeding
sone statins types are:
Lovastatin, Pravastatin, Simvastatin, Fluvastatin, Atorvastatin, Rosuvastatin and Pitavastatin.
Swerdlow DI, Preiss D, Kuchenbaecker KB, et al. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. The Lancet. 2014; doi:10.1016/S0140-6736(14)61183-1.